JUL 29, 2020 2:00 PM EDT

Route of 41BB/41BBL costimulation determines effector function of B7-H3-CAR.CD28ζ T cells

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Assistant Member, St. Jude Children's Research Hospital
    Biography

      Dr. DeRenzo is a pediatric oncologist and joined the Department of Bone Marrow Transplantation and Cellular Therapy at St. Jude Children's Research Hospital, where his goal is to develop and translate promising cell therapies from the laboratory into clinical trials for pediatric patients with solid tumors and brain tumors. Prior to joining St. Jude, he performed his general pediatric training at Case Western Reserve University/Rainbow Babies and Children's Hospital, and pediatric hematology/oncology training at Baylor College of Medicine/Texas Children's Cancer and Hematology Centers, where he stayed on as faculty until transitioning to his new position at St. Jude. He grew up in Southern New Jersey, outside of Philadelphia, and never imagined living in Cleveland, Houston, or Memphis, but has enjoyed living in each of these great cities, and getting to know people from diverse parts of the US and all over the world.


    Abstract

    B7-H3 is actively being explored as an immunotherapy target for pediatric patients with solid tumors using monoclonal antibodies or T cells expressing chimeric antigen receptors (CARs). B7-H3-CARs containing a 41BB costimulatory domain are currently favored by several groups based on preclinical studies. Here we initially performed a detailed analysis of T cells expressing B7-H3-CARs with different hinge/transmembrane (CD8α vs CD28) and CD28 or 41BB costimulatory domains (CD8α/CD28, CD8α/41BB, CD28/CD28, CD28/41BB). Only subtle differences in effector function were observed between CAR T-cell populations in vitro. However, CD8α/CD28-CAR T cells consistently outperformed other CAR T-cell populations in three animal models, resulting in a significant survival advantage. We next explored if adding 41BB signaling to CD8α/CD28-CAR T cells would further enhance effector function. Surprisingly, incorporating 41BB signaling into the CAR endodomain had detrimental effects, while expressing 41BBL on the surface of CD8α/CD28-CAR T cells enhanced their ability to kill tumor cells in repeat stimulation assays. Furthermore, 41BBL expression enhanced CD8α/CD28-CAR T-cell expansion in vivo and improved antitumor activity in 1 of 4 evaluated models. Thus, our study highlights the intricate interplay between CAR hinge/transmembrane and costimulatory domains. Based on our study, we selected CD8α/CD28-CAR T cells expressing 41BBL for early phase clinical testing.

     

    Learning Objectives:

    1. Understand B7-H3 as a promising immunotherapy target found at high levels on many tumor types

    2. Identify Optimal CAR design as a determined empirically for each new construct


    Show Resources
    You May Also Like
    FEB 19, 2020 11:00 AM PST
    C.E. CREDITS
    FEB 19, 2020 11:00 AM PST
    DATE: February 19, 2020TIME: 11:00am PST, 2:00pm EST...
    JUN 17, 2020 1:30 PM PDT
    C.E. CREDITS
    JUN 17, 2020 1:30 PM PDT
    Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
    MAR 11, 2020 6:00 AM PDT
    C.E. CREDITS
    MAR 11, 2020 6:00 AM PDT
    The locomotion of humans and other animals requires a seamless flow of information from sensory modalities all the way to the motor periphery. As such, locomotion is an excellent system for...
    APR 30, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 30, 2020 8:00 AM PDT
    DATE:April 30, 2020 TIME: 8AM PT, 11AM ET, 4PM BST, 5PM CEST Cytokinesis is the physical separation of two cells that occurs after the completion of mitosis. The mechanism underlying it is v...
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    AUG 26, 2020 8:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    AUG 26, 2020 8:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: August 26, 2020 TIME: 8:00 am PDT The host immune "recognition" of cancer forms the basis of modern tumor immmunotherapy, a highly targeted treatment option with the demonstr...
    Loading Comments...
    Show Resources